The latest announcement is out from Annovis Bio (ANVS).
Annovis Bio, Inc. has announced positive results for its leading Alzheimer’s drug, Buntanetap, demonstrating significant efficacy and safety in patients regardless of their genetic risk from Apolipoprotein E4. Following the announcement, the company detailed the drug’s prospects and future plans in a post-market webcast.
See more insights into ANVS stock on TipRanks’ Stock Analysis page.
